
Annual report 2023
added 12-27-2025
Biophytis SA EBITDA 2011-2026 | BPTS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Biophytis SA
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -26.8 M | -13.9 M | -15.7 M | -13.9 M | -9.7 M | -7.77 M | -3.12 M | -659 K | -468 K | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -468 K | -26.8 M | -10.2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-6.4 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Coherus BioSciences
CHRS
|
-180 M | $ 1.63 | - | $ 191 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.5 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 7.83 | - | $ 214 M | ||
|
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-11.9 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 4.4 | - | $ 1.31 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 17.3 | - | $ 809 M | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.59 | - | $ 423 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
BioNTech SE
BNTX
|
-1.4 B | $ 91.99 | - | $ 22.2 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | ||
|
Compugen Ltd.
CGEN
|
-34.6 M | $ 3.03 | - | $ 283 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.49 | - | $ 5.75 M | ||
|
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-18.7 M | $ 0.73 | - | $ 33.4 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 21.57 | - | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 9.24 | - | $ 264 M | ||
|
Esperion Therapeutics
ESPR
|
60.4 M | $ 3.12 | - | $ 649 M | ||
|
Eton Pharmaceuticals
ETON
|
3.2 M | $ 29.96 | - | $ 806 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Exelixis
EXEL
|
901 M | $ 51.1 | - | $ 13.9 B | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M |